Cargando…
Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma
OBJECTIVE: Primary mediastinal B-cell lymphoma (PMBCL) lacks standard treatment regimens. This study aimed to identify the disease’s clinical features and prognostic factors. METHODS: This retrospective study included 56 patients with PMBCL. Patient demographic details and clinicopathological charac...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743955/ https://www.ncbi.nlm.nih.gov/pubmed/35001690 http://dx.doi.org/10.1177/03000605211063027 |
_version_ | 1784630020317118464 |
---|---|
author | Liu, Yizhen Jiang, Jinjin Liu, Lianfang Wang, Zezhou Yu, Baohua Xia, Zuguang Zhang, Qunling Ji, Dongmei Liu, Xiaojian Lv, Fangfang Hong, Xiaonan Song, Shaoli Cao, Junning |
author_facet | Liu, Yizhen Jiang, Jinjin Liu, Lianfang Wang, Zezhou Yu, Baohua Xia, Zuguang Zhang, Qunling Ji, Dongmei Liu, Xiaojian Lv, Fangfang Hong, Xiaonan Song, Shaoli Cao, Junning |
author_sort | Liu, Yizhen |
collection | PubMed |
description | OBJECTIVE: Primary mediastinal B-cell lymphoma (PMBCL) lacks standard treatment regimens. This study aimed to identify the disease’s clinical features and prognostic factors. METHODS: This retrospective study included 56 patients with PMBCL. Patient demographic details and clinicopathological characteristics were summarized, and their effects on progression-free survival (PFS) and overall survival (OS) were analyzed. RESULTS: The median patient age was 29 years (range, 14–56). Twenty-two patients received DA-EPOCH-R (dose-adjusted etoposide, vincristine, and doxorubicin for 96 hours with bolus doses of cyclophosphamide and oral prednisone, as well as rituximab), and 34 patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Clinical/laboratory parameters, overall response rates, and 5-year PFS and OS rates did not differ between the treatment groups. Kaplan–Meier analysis indicated that late-stage disease and a higher International Prognostic Index (IPI) were associated with shorter PFS and OS. Furthermore, patients with B symptoms and first-line treatment non-responders exhibited worse OS. (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters, such as higher metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were corrected with shorter PFS. CONCLUSIONS: This study revealed that stage IV disease, higher IPI, and B symptoms were poor prognostic factors in patients with PMBCL. Significantly, higher MTV and TLG portended worse PFS. |
format | Online Article Text |
id | pubmed-8743955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87439552022-01-11 Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma Liu, Yizhen Jiang, Jinjin Liu, Lianfang Wang, Zezhou Yu, Baohua Xia, Zuguang Zhang, Qunling Ji, Dongmei Liu, Xiaojian Lv, Fangfang Hong, Xiaonan Song, Shaoli Cao, Junning J Int Med Res Retrospective Clinical Research Report OBJECTIVE: Primary mediastinal B-cell lymphoma (PMBCL) lacks standard treatment regimens. This study aimed to identify the disease’s clinical features and prognostic factors. METHODS: This retrospective study included 56 patients with PMBCL. Patient demographic details and clinicopathological characteristics were summarized, and their effects on progression-free survival (PFS) and overall survival (OS) were analyzed. RESULTS: The median patient age was 29 years (range, 14–56). Twenty-two patients received DA-EPOCH-R (dose-adjusted etoposide, vincristine, and doxorubicin for 96 hours with bolus doses of cyclophosphamide and oral prednisone, as well as rituximab), and 34 patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Clinical/laboratory parameters, overall response rates, and 5-year PFS and OS rates did not differ between the treatment groups. Kaplan–Meier analysis indicated that late-stage disease and a higher International Prognostic Index (IPI) were associated with shorter PFS and OS. Furthermore, patients with B symptoms and first-line treatment non-responders exhibited worse OS. (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters, such as higher metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were corrected with shorter PFS. CONCLUSIONS: This study revealed that stage IV disease, higher IPI, and B symptoms were poor prognostic factors in patients with PMBCL. Significantly, higher MTV and TLG portended worse PFS. SAGE Publications 2022-01-08 /pmc/articles/PMC8743955/ /pubmed/35001690 http://dx.doi.org/10.1177/03000605211063027 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Retrospective Clinical Research Report Liu, Yizhen Jiang, Jinjin Liu, Lianfang Wang, Zezhou Yu, Baohua Xia, Zuguang Zhang, Qunling Ji, Dongmei Liu, Xiaojian Lv, Fangfang Hong, Xiaonan Song, Shaoli Cao, Junning Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma |
title | Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma |
title_full | Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma |
title_fullStr | Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma |
title_full_unstemmed | Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma |
title_short | Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma |
title_sort | prognostic significance of clinical characteristics and (18)fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal b-cell lymphoma |
topic | Retrospective Clinical Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743955/ https://www.ncbi.nlm.nih.gov/pubmed/35001690 http://dx.doi.org/10.1177/03000605211063027 |
work_keys_str_mv | AT liuyizhen prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT jiangjinjin prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT liulianfang prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT wangzezhou prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT yubaohua prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT xiazuguang prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT zhangqunling prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT jidongmei prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT liuxiaojian prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT lvfangfang prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT hongxiaonan prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT songshaoli prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma AT caojunning prognosticsignificanceofclinicalcharacteristicsand18fluorodeoxyglucosepositronemissiontomographycomputedtomographyquantitativeparametersinpatientswithprimarymediastinalbcelllymphoma |